Discover more from BioPharma Observer
2022
Book Recommendations: Summer Reading List 2022 BioPharma Observer
2021
“Biopharma’s Racial Justice Work is a Start, But More Needs to Happen” Timmerman Report June 23, 2021
“Summer Reading List 2021” BioPharma Observer June 15, 2021
“Vaccine Passports: More Problematic Than Useful?” Biopharma from Technology Networks March 26, 2021
2020
“Summer Reading List 2020” BioPharma Observer June 5, 2020
“Vaccine Opponents and Voter Fraud Zealots: A Marriage Made in Conspiracy Heaven” Medium June 5, 2020
“Advice for Head and Neck Cancer Patients During Covid-19” Head and Neck Cancer Association Website May 6, 2020
“If Pharma Helps Quench the Covid-19 Pandemic, What Will It Want in Return?” Stat First Opinion April 21, 2020
“Deadly Infectious Viruses Come From Many Places Besides China” BioPharma Observer March 19, 2020
2019
“While Searching for the Perfect Vaccine, Keep Using the Very Good” Scientific American Observations, Oct. 4, 2019
“BioPharma Haiku Round 6” BioPharma Observer Aug. 18, 2019
“Book Recommendations: Summer Reading List 2019” BioPharma Observer June 11, 2019
“Don’t Get Theranosed: Detecting Bioscience BS” Biopharma Observer April 30, 2019
“Pharma’s Tarnished Reputation Helps Fuel the Anti-Vaccine Movement” Stat First Opinion Feb. 26, 2019
“BioMedical Ethics: Moral Dilemmas with Lives in the Balance” BioPharma Observer Jan. 21, 2019
2018
“Receiving Good Healthcare Is Now A Patient’s Responsibility” BioPharma Observer Nov. 29, 2018
“HPV Cancer Resources: My New Website for Parents, Patients, Partners, and Healthcare Providers” BioPharma Observer Oct. 22, 2018
“Autism in Dogs: People Embrace Conspiracy Theories, So Why Not Junk Science?” BioPharma Observer Sept. 24, 2018
“We’ve Got Very Effective Disease Treatments. Too Bad They’re Not Being Used.” BioPharma Observer August 20, 2018
“BioPHarma Haiku Round 5” BioPharma Observer July 16, 2018
“Book Recommendations: Summer Reading List 2018” BioPharma Observer June 11, 2018
“Bias and Self-Delusion are a Problem in Both Politics and Science” BioPharma Observer May 14, 2018
“Artificial Intelligence? I’d Settle for the Real Thing!” BioPharma Observer April 9, 2018
“The HPV Vaccine: Preventing Cancer Beats Treating It” Biopharma Observer March 5, 2018
“Data Irreproducibility: The “Waste, Fraud, and Abuse” of Scientific Research” BioPharma Observer Feb. 12, 2018
“Is Pharma Really Facing It’s Demise?” BioPharma Observer Jan. 22, 2018
2017
“What to Read to Get the Latest BioPharma/Healthcare Info” BioPharma Observer Dec. 11, 2017
“Non-Compete Agreements: Dangerous Liaisons” BioPharma Observer Nov. 13, 2017
“Sci-Hub vs. iPubSci: Another Look at Accessing Unaffordable Science Journals” BioPharma Observer Oct. 16, 2017
“Health Insurance Improves Patients Lives” BioPharma Observer Sept. 21, 2017
“Rock Lyrics Predicted Drug Discoveries” BioPharma Observer August 15, 2017
“BioPHarma Haiku Round 4” BioPharma Observer July 11, 2017
“Summer Reading List 2017: Even More True Tales to Inform and Amuse You” BioPharma Observer June 6, 2017
“So What Did the March for Science Accomplish?” BioPharma Observer May 2nd, 2017
“President Puts America’s Freedoms in Peril” Albany Times Union April 15 2017
“12 Lessons Learned from My Cancer Diagnosis” Patient Power website, April 6, 2017
“Why I’m Joining in the March for Science” BioPharma Observer March 7, 2017
“BioPharma and Hollywood: Land of the Blockbusters” BioPharma Observer Feb. 21, 2017
“Hollywood and BioPharma: Differentiated by Unique Economic Models” BioPharma Observer Feb. 21, 2017
“Would Government Buyouts of Pharma Companies Really Be A Good Way To Lower Drug Prices?” BioPharma Observer Feb. 7, 2017
“Consequences: In a Post-Truth World, Scientific Progress Goes Boink” BioPharma Observer Jan. 17, 2017
2016
“Why Even Superman Would Fear Donald Trump” BioPharma Observer Nov. 29, 2016
“Not Accepting the Outcome When the (FDA) Vote Doesn’t Go Your Way” BioPharma Observer Nov. 1, 2016
“The Covenant Between BioPharma Companies and Their Customers” BioPharma Observer Oct. 11, 2016
“How Can You Make Money in Biotech If Only One In Ten Companies Turns A Profit?” BioPharma Observer Sept. 6, 2016
“BioPharmaceutical Haiku, Round Three” BioPharma Observer August 9, 2016
“Can Changing A Biotech Company’s Name Really Alter Its Fortunes?” BioPharma Observer July 12, 2016
“Summer Reading List 2016: More True Tales to Inform and Amuse You” BioPharma Observer June 7, 2016
“Which Bush Had the Greatest Impact on American Science?” BioPharma Observer April 19, 2016
“True or False: Only Two Out of Ten Drugs Earns Back Its Development Costs?” BioPharma Observer March 29, 2016
“Why Sci-Hub Won’t Lead to the Downfall of Science Publishers” BioPharma Observer March 1, 2016
“Cancer Immunotherapy: It’s (Almost) All About the Combo” BioPharma Observer Feb. 9, 2016
“Drug Pricing: Lack of Transparency and Trust Compound the Problem” BioPharma Observer Jan. 26, 2016
2015
“Martin Shkreli, Biopharma’s 21St Century Robber Baron” Fierce Biotech Dec. 21, 2015
"BioPharma CEOs, VCs, and Hedge Fund Managers: Fifty Shades of Greed" Xconomy Oct. 7, 2015
"Pharma Plays The “Value” Card: Drug Spending Then And Now" Xconomy Sept. 14, 2015
"Dr. Frances Kelsey: American Hero, Government Regulator" Xconomy August 12, 2015
"Drug Discovery in Seattle 2015: An Updated History" Xconomy August 3, 2015
"BioPharmaceutical Haiku, Round Two" Xconomy July 6, 2015
"Summer Reading List: True Tales That Will Inspire and Educate You" Xconomy June 1, 2015
"The Innovation Challenge: Assessing BioPharma Startups" Xconomy May 4, 2015
"Academia vs. BioPharma: Young Scientists Between A Rock and A Hard Place" Xconomy April 6, 2015
"Cancer Immunotherapy Companies: Looking Forward and Looking Back" Xconomy March 2, 2015
"Resistance Is Futile: Why That’s A Good Thing In Biomedicine" Xconomy Feb. 9, 2015
"Technology Upgrades: Welcome to My Nightmare (Yours Too?)" Xconomy Jan. 6, 2015
2014
"Prescription Drug Pricing: The Fine Line Between Value and Greed" Xconomy Dec. 2, 2014
"Beg, Borrow, or Steal: Accessing Unaffordable Science Journals" Xconomy Nov. 10, 2014
"What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies" Xconomy Oct.6, 2014
"What Seattle Needs (Part 2): Dealing With Amgen’s Upcoming Departure" Xconomy Oct.7, 2014
"What Seattle Needs (Part 3): Working Together to Revitalize Biotech" Xconomy Oct.8, 2014
"Which Countries Excel in Creating New Drugs? It’s Complicated" Xconomy September 2, 2014
"Military Strategies Being Used in the War on Cancer" Xconomy August 4, 2014
"Saying Nothing With Style: The 2014 BioPharma Edition of BS Bingo" Xconomy June 30, 2014
"Prostate Cancer Screening: Seduction of the Innocent" Xconomy May 28, 2014
"BioPharma Learns from Marvel, Begins Real Life Search for “X-Men”" Xconomy April 30, 2014
"Appearing Briefly at Your Next Conference: “Whac-A-Mole” Speakers" Xconomy March 31, 2014
"Why It's Time to Retire the Term "Life Sciences"" Xconomy March 4, 2014
“BioPharmaceutical Haiku” Xconomy Feb. 3, 2014
“Bad Statistics, and Bad Training, Are Sabotaging Drug Discovery” Xconomy Jan. 6, 2014
2013
“Got Cancer? Sorry, There’s No App for That” Xconomy Jan. 10, 2013
“The Academy Awards: Biopharma Edition” Xconomy Feb. 20, 2013
“Has The Pendulum Swung Too Far in Favor of Rare Diseases?” Xconomy March 14, 2013
“The Devil is in the Details: What BioPharma Press Releases Don’t Say” Xconomy April 24, 2013
“Assigning Credit and Blame to Biopharma R&D Chiefs” Xconomy May 29, 2013
“Baseball and Biopharma: More Alike Than You Might Realize” Xconomy July 3, 2013
“Lost in Translation: The Novice’s Guide to BioPharma Idioms” Xconomy August 7, 2013
"Are Some Degrees Better than Others for Big Pharma Leaders?" Xconomy, Sept. 9, 2013
“Science: The Missing Ingredient in the GMO Food Labeling Debate” Xconomy Oct. 8, 2013
“Time to Come Clean: Why A High-Tech Guy Envies the Low-Tech World” Xconomy Nov. 12, 2013
"Modern Day Scrooges Are Ruining Our Health Care System" Xconomy Dec. 3, 2013
2012
“Will New Business Models Enhance or Endanger Drug Discovery?” Xconomy Feb. 16, 2012
“A Seussian Guide to BioPharma” Xconomy March 13, 2012
“BioPharma Needs a Safe, Reliable Way to Fix Broken Genes” Xconomy April 11, 2012
“Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill?” Xconomy May 3, 2012
“Basic Biology: The Complex Core of Drug Discovery” Xconomy May 30, 2012
“Clash of the BioPharma Titans Looms Over Biosimilars” Xconomy June 25, 2012
“Woeful Websites: How to Guarantee Your Start-Up Won’t Get Funding” Xconomy July 23, 2012
“Pharma Heads Back to School” Burill Report Podcast August 13, 2012
“Would Longer Drug Patents Really Lead to Lower Drug Prices?” Xconomy Sept. 5, 2012
"The Reproducibility Initiative: A Good Idea in Theory that Won’t Work in Practice" Xconomy Oct. 2, 2012
“Rescuing Patent-Less Proteins from the Drug Development Dustbin” Xconomy Nov. 6, 2012
“The Enduring Success of a Healthcare Radical” Xconomy Dec. 4, 2012
2011
“What Does Biotech Really Suffer From: Information Overload, or Underload?” Xconomy January 18, 2011
“Advice Received, But Not Taken: Tales from the Biotech Trenches” Xconomy March 7, 2011
“Who’s Going to Pay for Future Drug Development?” (Part 1) Xconomy March 22, 2011
“Who’s Going to Pay for Future Drug Development?” (Part 2) Xconomy March 23, 2011
“Why Do I Love Drug Regulation? Simple: It Keeps Us Safe” Xconomy April 15, 2011
“Pharma-Academic Alliances: What the Numbers Don’t Tell You” Xconomy May 10, 2011
“This Drug Didn’t Work for Me. May I Have My $88,000 Back, Please?” Xconomy June 30, 2011
“Industry Access to the Literature” Nature Biotechnology Vol. 29 No.7 pp 571-572, July 2011
“(Mis)Understanding Drug Discovery: It’s Much Harder Than Rocket Science” Xconomy Sept. 7, 2011
“Biopharma Industry Meetings Could Use Some Fresh Voices” Xconomy Nov. 1, 2011
“Biopharmaceuticals: Nothing Compares to You” Xconomy Nov. 17, 2011
“iPubSci: An Alternative to Unaffordable Science Journals” Xconomy Dec. 5, 2011
2010
"The Pharmaceutical R&D Model is Broken. Here's How to Fix It" Xconomy March 5, 2010
“Biotech’s Second Big Win in Healthcare Reform: A Tax Credit Bonanza” Xconomy April 8, 2010
“The Bleeding Edge of Pharma: Collaborations, Science, and Finance” European BioPharmaceutical Review April 2010
“Biotech’s $1 Billion Tax Credits are Up for Grabs! OK, Now Everybody Relax” Xconomy May 21, 2010
“Biotech Drug Discovery in Seattle: A Look Back” Xconomy June 11, 2010
“ZymoGenetics Will Be Missed. How Seattle Biotech Can Recovery and Thrive” Xconomy September 21, 2010
“The Challenge of Understanding Biotech: Sifting Through the Fog and Jargon” Xconomy October 20, 2010
“The Winners of the IRS Biotech Grant Program Are ....” Xconomy November 3, 2010
“The Myth of the ‘Patent Cliff’” Xconomy November 29, 2010
2009
"Two Simple Ways to Revitalize Seattle Biotech" Xconomy February 9, 2009
"Measuring Success in the Biotech World" Xconomy April 28, 2009
"Forget the Shortcuts: Creating a Truly Innovative Biotech Culture" Xconomy July 27, 2009
"Why Big Pharma Wants to be Like Big Biotech" Xconomy August 19, 2009
"Don't Touch My Bags if You Please, Mr. Customs Man" Xconomy October 5, 2009
"Hollywood Sees Corruption in Pharma, and Suddenly Scientists are the Bad Guys" Xconomy December 7, 2009
“A Brief Year-End Review of Seattle Biotech” Xconomy December 31, 2009